Dorzolamide Eye Drops Manufacturer in India

Dorzolamide inhibits carbonic anhydrase II (CA-II) in the ciliary body epithelium — an enzyme essential for bicarbonate ion production in aqueous humour formation. By blocking CA-II, Dorzolamide reduces aqueous humour production and consequently lowers intraocular pressure by approximately 15–20% as monotherapy. When combined with Timolol, the two complementary mechanisms of aqueous suppression provide additive IOP reduction of 25–35%.

Dorzolamide is preferred over or used alongside Timolol in: patients with asthma, severe COPD or significant bradycardia where systemic beta-blockade from Timolol is contraindicated, patients requiring additional IOP lowering beyond what Timolol alone achieves, and patients who develop intolerance to beta-blocker eye drops. Dorzolamide can be used safely in these populations as its systemic absorption does not affect cardiac or respiratory function significantly.

Yes. 9M India manufactures Dorzolamide 2% + Timolol 0.5% fixed-dose combination eye drops — one of the most widely prescribed antiglaucoma combinations globally. This combination provides complementary dual aqueous suppression (CAI + beta-blocker) with twice-daily dosing, significantly improving compliance compared to using the two agents separately at different times.

Dorzolamide 2% as monotherapy is dosed three times daily (morning, midday, evening). When used in combination with Timolol as a fixed-dose formulation (Dorzolamide + Timolol), dosing is reduced to twice daily — the primary compliance advantage of the fixed-dose combination. Patients with sulphonamide allergy should be screened before prescribing as Dorzolamide is a sulphonamide derivative.

Yes. Dorzolamide is frequently added as third-line therapy in patients on Latanoprost + Timolol who require additional IOP lowering — or as a Timolol-free alternative in beta-blocker contraindicated patients already on Latanoprost. The combination of a prostaglandin analogue (Latanoprost) + CAI (Dorzolamide) provides effective dual therapy without systemic beta-blockade risk.

9M India exports Dorzolamide eye drops to Phase 1 markets including the UAE, Iraq, Egypt, Kazakhstan, Sri Lanka and others across the Middle East, CIS, Africa and ASEAN. Dorzolamide — both as monotherapy and in combination with Timolol — is in growing demand in these markets as glaucoma treatment protocols increasingly move toward combination therapy for better IOP control and compliance.

Documentation available includes WHO-GMP Certificate, DCGI Manufacturing Licence, CoPP, batch- wise CoA (sterility, particulate matter, pH, assay, preservative content), ICH Zone IVb stability data and CTD/ACTD dossiers on request for Dorzolamide 2% monotherapy and Dorzolamide + Timolol fixed-dose combination eye drops.